UBS Group AG Has $3.15 Million Stake in MoonLake Immunotherapeutics $MLTX

Key Points

• UBS Group AG significantly increased its MoonLake Immunotherapeutics stake by 183.4% in the fourth quarter, ending with 239,020 shares valued at about $3.15 million.
• Analyst sentiment is mixed but improving, with several firms raising price targets; the current consensus rating is Hold and the average price target is $23.85.
• MoonLake reported a quarterly EPS loss of $0.98, wider than expected, while insiders have been active sellers, including a large director sale and CEO stock sale in recent months.

UBS Group AG boosted its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 183.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 239,020 shares of the company's stock after purchasing an additional 154,673 shares during the period. UBS Group AG owned about 0.37% of MoonLake Immunotherapeutics worth $3,150,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of MLTX. FNY Investment Advisers LLC bought a new stake in MoonLake Immunotherapeutics during the third quarter valued at $28,000. Bank of America Corp DE boosted its position in MoonLake Immunotherapeutics by 64.7% during the third quarter. Bank of America Corp DE now owns 4,532 shares of the company's stock valued at $32,000 after acquiring an additional 1,781 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in MoonLake Immunotherapeutics by 115.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company's stock valued at $42,000 after acquiring an additional 3,166 shares during the last quarter. Covestor Ltd bought a new stake in MoonLake Immunotherapeutics during the third quarter valued at $46,000. Finally, BNP Paribas Financial Markets boosted its position in MoonLake Immunotherapeutics by 18.9% during the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company's stock valued at $52,000 after acquiring an additional 1,158 shares during the last quarter. Institutional investors own 93.85% of the company's stock.

Analyst Ratings Changes

MLTX has been the topic of a number of research analyst reports. Wolfe Research raised shares of MoonLake Immunotherapeutics from an "underperform" rating to an "outperform" rating and upped their price target for the company from $12.00 to $24.00 in a research report on Monday, March 23rd. Needham & Company LLC upped their price target on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a "buy" rating in a research report on Tuesday, May 12th. Royal Bank Of Canada upped their price target on shares of MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the company a "sector perform" rating in a research report on Monday, March 2nd. Zacks Research raised shares of MoonLake Immunotherapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 24th. Finally, Oppenheimer increased their price objective on shares of MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 24th. Nine analysts have rated the stock with a Buy rating, four have given a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $23.85.

MoonLake Immunotherapeutics Price Performance

MLTX stock opened at $18.19 on Monday. The stock has a market capitalization of $1.30 billion, a PE ratio of -4.70 and a beta of 1.01. The company's 50-day moving average is $17.42 and its 200-day moving average is $15.81. The company has a debt-to-equity ratio of 0.39, a current ratio of 8.60 and a quick ratio of 8.60. MoonLake Immunotherapeutics has a 1 year low of $5.95 and a 1 year high of $62.75.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.07). Equities research analysts expect that MoonLake Immunotherapeutics will post -3.71 EPS for the current fiscal year.

Insider Transactions at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, Director Bvf Partners L. P/Il sold 3,750,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $16.79, for a total transaction of $62,962,500.00. Following the completion of the transaction, the director owned 1,039,238 shares in the company, valued at approximately $17,448,806.02. The trade was a 78.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Da Silva Jorge Santos sold 98,127 shares of MoonLake Immunotherapeutics stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $18.41, for a total value of $1,806,518.07. Following the transaction, the chief executive officer owned 2,976,766 shares of the company's stock, valued at $54,802,262.06. This trade represents a 3.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,900,000 shares of company stock worth $65,714,663 in the last three months. Insiders own 12.02% of the company's stock.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Want to see what other hedge funds are holding MLTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.